The study, published in the Journal of Clinical Pathways, analyzed data from nearly 13,500 patients who received chemotherapy between Sep. 1, 2020, and Aug. 31, 2022. Patients who underwent home redirection were 32 percent less likely to have incidences of neutropenia, fever, pneumonia and sepsis.
The odds of same-day pegfilgrastim administration were 43 percent lower in patients who underwent home redirection, according to the study.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
